Overview

• Immunome reports Q3 net loss of $57.5 mln,

• Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027

• Research and development expenses for Q3 were $49.2 mln

Outlook

• Varegacestat: Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025

• Immunome expects current cash to fund operations into 2027

Result Drivers

• R&D INVESTMENT - Significant investment in R&D with expenses totaling $49.2 mln for Q3

• General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35

Press Release: ID:nBw2ZyRqwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)